There’s no denying the popularity of weight-loss drugs in the United States, with one in eight adults relying on GLP-1s to ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...

'It only makes sense that the weight of passengers impacts costs,' an equity analyst for a financial firm said ...

GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting "GLP-3s," claiming they are taking obesity medications to the next level. GLP-1 (glucagon-like peptide-1) ...

WASHINGTON -- New obesity drugs are showing promising results in helping some people shed pounds but the injections will remain out of reach for millions of older Americans because Medicare is ...

DURHAM, N.C. (WTVD) -- A popular weight loss drug made in the Triangle is now available in pill form. On Monday, pharmaceutical company Novo Nordisk announced FDA approval of a new Wegovy pill, the ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Serena Williams said that roughly a year after starting a weight loss drug, she is the healthiest she has ever been and has lost 34 pounds.

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...